KR920006277A - 칼슘 흡수 억제제 - Google Patents

칼슘 흡수 억제제 Download PDF

Info

Publication number
KR920006277A
KR920006277A KR1019910016529A KR910016529A KR920006277A KR 920006277 A KR920006277 A KR 920006277A KR 1019910016529 A KR1019910016529 A KR 1019910016529A KR 910016529 A KR910016529 A KR 910016529A KR 920006277 A KR920006277 A KR 920006277A
Authority
KR
South Korea
Prior art keywords
phenyl
compound
compound according
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
KR1019910016529A
Other languages
English (en)
Other versions
KR100217806B1 (ko
Inventor
죠셉 디너스데인 로버트
스테펜 사볼 제프레이
알렌 디이케마 케이스
Original Assignee
게리 디. 스트리트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 게리 디. 스트리트
Publication of KR920006277A publication Critical patent/KR920006277A/ko
Application granted granted Critical
Publication of KR100217806B1 publication Critical patent/KR100217806B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/207—Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon triple bonds as unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/292—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with chromium derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
    • C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

내용 없음

Description

칼슘 흡수 억제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 fMLP처리후에 래트 호증구 세포내 칼슘 수준에 대한 MDL 101, 097의 효과를 나타낸다.

Claims (34)

  1. 일반식(1)의 화합물 또는 이의 약제학적으로 허용되는 염.
    (1)
    상기식에서 R1R2및 R3는 각각 독립적으로 수소; C1-C6알킬; C1-C6알콕시; 할로겐; -N(Y1)(Y2)(여기에서, Y1및 Y2는 각각 독립적으로 수소 또는 C1-C6알킬이다); 또는 XZ-(Ar)-(CH2)n-O-[여기에서, Ar은 페닐 또는 나프틸이고, n은 0또는 1이며, X는C1-C6알콕시 또는 -N(Y1)(Y2)(여기에서, Y1및 Y2는 상기 정의한 바와같다)이고, Z는 0, 1, 또는 2이다]이다.
  2. 제1항에 있어서, 1-페닐-3-(3,4,5-트리메톡시페닐)-2-프로핀-1-온인 화합물.
  3. 제1항에 있어서, 1-페닐-3-[3-(4-메톡시벤질옥시)페닐]-2-프로핀-1-온인 화합물.
  4. 제1항에 있어서, 1-페닐-3-[(4-벤질옥시)페닐]-2-프로핀-1-온인 화합물.
  5. 제1항에 있어서, 1-(3,4,5-트리메톡시페닐)-3-페닐-2-프로핀-1-온인 화합물.
  6. 제1항에 있어서, 1-페닐-3-페닐-2-프로핀-1-온인 화합물.
  7. 제1항에 있어서, 1-페닐-3-(3-벤질옥시페닐)-2-프로핀-1-온인 화합물.
  8. 제1항에 있어서, 1-(4-디메틸아미노페닐)-3-(3-벤질옥시페닐)-2-프로핀-1-온인 화합물.
  9. 제1항에 있어서, 1-(3-벤질옥시페닐)-3-(3-벤질옥시페닐)-2-프로핀-1-온인 화합물.
  10. 제1항에 있어서, 1-페닐-[3-(4-에톡시벤질옥시)페닐]-2-프로핀-1-온인 화합물.
  11. 제1항에 있어서, 1-페닐-[3-(4-디메틸아미노)벤질옥시]페닐-2-프로핀-1-온인 화합물.
  12. 백혈구에서의 칼슘 흡수의 억제가 필요한 환자에게 칼슘 흡수 억제 유효량의 제1항에 따를 화합물을 투여함을 특징으로 하여, 상기 환자에게 백혈구에서의 칼슘 흡수를 억제하는 방법.
  13. 제12항에 있어서, 환자가 면역 질환을 앓는 방법.
  14. 제12항 또는 제13항에 있어서, 환자가 류마티스성 관절염을 앓는 방법.
  15. 제12항 또는 13항에 있어서, 환자가 면역 맥관염을 앓는 방법.
  16. 제12항에 있어서, 환자가 염증, 질환을 앓는 방법.
  17. 제12항에 있어서, 환자가 호증구성 피부병을 앓는 방법.
  18. 혈소관에서의 칼슘 흡수의 억제가 필요한 환자에게 칼슘 흡수 억제 유요량의 제1항에 따른 화합물을 투여함을 특징으로 하여 상기 환자에게 혈소판에서의 칼슘 흡수를 억제하는 방법.
  19. 제18항에 있어서, 환자가 심장맥관 장애를 앓는 방법.
  20. 제18항에 있어서, 환자가 심근경색증을 앓는 방법.
  21. 제18항에 있어서, 환자가 허혈성 재관류 손상을 앓는 방법.
  22. 제1내지 제11항중 어느 한항에 따른 화합물을 담체와의 혼합물로 포함하는 약제학적 조성물.
  23. 약제학적 활성 물질로서 사용하기 위한 제1내지 제11항중 어느 한항에 따를 화합물 또는 이의 약제학적으로 허용되는 염 또는 이의 혼합물.
  24. 백혈구에서의 칼슘 흡수 억제제로서의 치료용 약제학적 조성물을 제조하기 위한 제1내지 제11항중 어느 한항에 따른 화합물 또는 이의 약제학적으로 허용되는 염 또는 이의 혼합물.
  25. 면역질환 치료용 약제학적 조성물을 제조하기 위한 제24항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  26. 류머티스성 관절염 치료용 약제학적 조성물을 제조하기 위한 제24항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  27. 면역 맥관염 치료용 약제학적 조성물을 제조하기 위한 제24항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  28. 염증 질환 치료용 약제학적 조성물을 제조하기 위한 제24항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  29. 호중구성 피부병 치료용 약제학적 조성물을 제조하기 위한 제24항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  30. 혈소판에서의 칼슘 흡수 억제제로서의 치료용 약제학적 조성물을 제조하기 위한 제1내지 제11항중 어느 한항에 따른 화합물 또는 이의 약제학적으로 허용되는 염 또는 이의 혼합물.
  31. 심잘혈관장애 치료용 약제학적 조성물을 제조하기 위한 제30항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  32. 허혈성 재관류 손상 치료용 약제학적 조성물을 제조하기 위한 제30항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  33. 심근경색증 치료용 약제학적 조성물을 제조하기 위한 제30항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  34. 반응도식 A에 따라 제1내지 제11항중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용되는 염을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910016529A 1990-09-20 1991-09-20 칼슘 흡수 억제제, 이의 제조방법 및 이를 함유하는 약제학적 조성물 KR100217806B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58575990A 1990-09-20 1990-09-20
US07/585,759 1990-09-20
US7/585,759 1990-09-20

Publications (2)

Publication Number Publication Date
KR920006277A true KR920006277A (ko) 1992-04-27
KR100217806B1 KR100217806B1 (ko) 1999-09-01

Family

ID=24342836

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910016529A KR100217806B1 (ko) 1990-09-20 1991-09-20 칼슘 흡수 억제제, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (17)

Country Link
EP (1) EP0476658B1 (ko)
JP (1) JP3296836B2 (ko)
KR (1) KR100217806B1 (ko)
CN (1) CN1059901A (ko)
AT (1) ATE130289T1 (ko)
AU (1) AU635156B2 (ko)
CA (1) CA2051501C (ko)
DE (1) DE69114635T2 (ko)
ES (1) ES2082074T3 (ko)
FI (1) FI914408A (ko)
HU (1) HUT59076A (ko)
IE (1) IE913298A1 (ko)
IL (1) IL99511A0 (ko)
NO (1) NO913683L (ko)
NZ (1) NZ239865A (ko)
PT (1) PT99012A (ko)
ZA (1) ZA917369B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985935A (en) * 1992-03-06 1999-11-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
CA2128991A1 (en) * 1993-08-02 1995-02-03 Hisao Takayanagi Benzoylacetylene derivatives
FR2713635B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés propynyl bi-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1465854A4 (en) 2001-12-19 2005-06-08 Atherogenics Inc CHALCONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
EP2285421B1 (en) 2008-05-02 2018-04-11 Novadaq Technologies ULC Methods for production and use of substance-loaded erythrocytes for observation and treatment of microvascular hemodynamics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1111337A (en) * 1964-07-24 1968-04-24 Fisons Pharmaceuticals Ltd Substituted aralkyl alcohols
BE758735A (fr) * 1969-11-14 1971-05-10 Hoffmann La Roche Composes acetyleniques
CA1137082A (en) * 1979-05-23 1982-12-07 Isao Umeda Substituted acetophenones and process therefor
JPS6385526A (ja) * 1986-09-30 1988-04-16 Nippon Oil & Fats Co Ltd 非線形光学材料
JPH0669386B2 (ja) * 1987-03-18 1994-09-07 協和醗酵工業株式会社 ５′−イノシン酸の製造法
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives

Also Published As

Publication number Publication date
ATE130289T1 (de) 1995-12-15
KR100217806B1 (ko) 1999-09-01
ES2082074T3 (es) 1996-03-16
DE69114635D1 (de) 1995-12-21
HU913011D0 (en) 1992-01-28
NZ239865A (en) 1993-12-23
HUT59076A (en) 1992-04-28
IL99511A0 (en) 1992-08-18
EP0476658A1 (en) 1992-03-25
CN1059901A (zh) 1992-04-01
CA2051501A1 (en) 1992-03-21
IE913298A1 (en) 1992-02-25
AU8452891A (en) 1992-03-26
ZA917369B (en) 1992-06-24
AU635156B2 (en) 1993-03-11
CA2051501C (en) 2004-02-17
PT99012A (pt) 1992-08-31
JPH0725812A (ja) 1995-01-27
DE69114635T2 (de) 1996-04-18
FI914408A (fi) 1992-03-21
NO913683D0 (no) 1991-09-19
EP0476658B1 (en) 1995-11-15
JP3296836B2 (ja) 2002-07-02
NO913683L (no) 1992-03-23
FI914408A0 (fi) 1991-09-19

Similar Documents

Publication Publication Date Title
KR920006316A (ko) 칼슘 흡수 억제제
FR2435471A1 (fr) Derives de dihydropyridine, procedes d'obtention et compositions pharmaceutiques en contenant
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
SE8704747L (sv) Farmaceutisk komposition
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
FR2658818B1 (fr) Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
ATE85976T1 (de) Pharmakologisch aktive derivate von tryptophan und diese enthaltende pharmazeutische zusammensetzungen.
RU94044454A (ru) Ингибитор аутоимунных заболеваний
KR890001966A (ko) 함염성 아릴 유도체
KR920006277A (ko) 칼슘 흡수 억제제
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
PT77666B (fr) Procede de preparation de nouveaux derives de la nitrosouree
ES433860A1 (es) Procedimiento de preparacion de derivados del acido ciclo- pentano-carboxilico.
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
DE68900516D1 (de) Therapeutische mittel zur behandlung von magengeschwueren.
KR920006317A (ko) 칼슘 흡수 억제제
FR2369216A1 (fr) Produits pour le traitement d'eaux, contenant des acides acylimino diacetiques
KR920011490A (ko) 척추 손상으로 인한 반사이상항진 치료용 3-아릴-5-알킬티오-4h-1, 2, 4-트리아졸
KR950703528A (ko) 프로스타글란딘 e₁유연체
KR890014116A (ko) 고혈압치료 혼합물
ES8201150A1 (es) Procedimiento para la preparacion de acidos 5-sulfamoilorta-nilicos
TH6256EX (th) อนุพันธ์ แอริล สารต่อต้านการอักเสบ
RU92016559A (ru) Производные диалкокси-пиридинилбензимидазола, фармацевтическая композиция, способ ингибирования или лечения, способ их получения, применение и промежуточные соединения

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030528

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee